MedTrace Logo

Long-term Benefit of MPA in Liver Transplantation

NCT05707520 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-02-01

No results posted yet for this study

Summary

MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.

Conditions

  • Liver Transplant Rejection
  • Immunosuppressant Adverse Reaction

Interventions

DRUG

enteric-coated mycophenolate (MPAs)

Immunosuppression protocol with enteric-coated mycophenolate sodium

DRUG

None MPA

Immunosuppression protocol without enteric-coated mycophenolate sodium

Sponsors & Collaborators

  • Shulan (Hangzhou) Hospital

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Beijing YouAn Hospital

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • The Third Xiangya Hospital of Central South University

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Hebei Medical University Third Hospital

    collaborator OTHER

  • People's Hospital of Guangxi Zhuang Autonomous Region

    collaborator OTHER

  • Beijing Friendship Hospital

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-04
Primary Completion
2023-06-30
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05707520 on ClinicalTrials.gov